Oligodendrocyte Extracellular Vesicles for Multi-Antigen MS Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antigen-specific therapies for multiple sclerosis (MS) are ineffective due to the uncertainty about the specific myelin components targeted by the immune system, making it difficult to develop targeted treatments.
Innovation Solution
Administering oligodendrocyte-derived extracellular vesicles (Ol-EVs) that naturally contain myelin antigens such as myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and myelin proteolipid protein (PLP), which induce immunosuppressive monocytes and restore immune tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigen-specific therapies are developed for multiple sclerosis, then targeted treatment effectiveness should improve, but the uncertainty about specific myelin components targeted by the immune system makes therapy development difficult
Solution Approach 1:
The patent uses oligodendrocyte-derived extracellular vesicles that naturally contain multiple myelin antigens (MBP, MOG, PLP, MAG, CNP) simultaneously, creating a universal therapy that addresses multiple potential autoimmune targets in one treatment rather than requiring separate therapies for each antigen
Solution Approach 2:
The extracellular vesicles serve as an intermediary carrier that delivers multiple myelin antigens to the immune system in a controlled manner, facilitating immune tolerance induction without requiring direct administration of individual antigens or complex combination therapies
2Reliability
If oligodendrocyte-derived extracellular vesicles are administered, then immune tolerance is restored and MS symptoms are suppressed, but the mechanism of action requires detailed biological processes
Solution Approach 1:
The oligodendrocyte-derived extracellular vesicles naturally contain the full spectrum of myelin antigens needed for comprehensive immune tolerance induction, allowing the treatment to work through the body's existing immune regulation mechanisms without requiring additional complex delivery systems or combination therapies
Data Source
AI summary
In various aspects and embodiments the invention provides a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering to the subject an effective amount of an oligodendrocyte-derived extracellular vesicle.